MARKET

HRTX

HRTX

Heron Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.18
+0.08
+0.66%
Opening 10:27 09/20 EDT
OPEN
11.86
PREV CLOSE
12.10
HIGH
12.20
LOW
11.82
VOLUME
174.19K
TURNOVER
--
52 WEEK HIGH
22.40
52 WEEK LOW
10.10
MARKET CAP
1.24B
P/E (TTM)
-4.8331
1D
5D
1M
3M
1Y
5Y
2 “Strong Buy” Stocks With Heavy Short Interest
Right now, markets are giving investors opposing trends simultaneously. The S&P and NASDAQ have posted strong year-to-date gains. At the same time, however, Wall Street strategists are growing more concerned that a slowing U.S. economy could derail the sto...
TipRanks · 6d ago
Tang Capital Management Llc Buys Heron Therapeutics Inc, Vincerx Pharma Inc, Altimmune Inc, ...
GuruFocus News · 08/24 18:38
Baker Bros. Advisors Lp Buys Verve Therapeutics Inc, Nurix Therapeutics Inc, Legend Biotech ...
GuruFocus News · 08/24 18:38
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
Ubs Oconnor Llc Buys , , , Sells , RealPage Inc,
GuruFocus News · 08/17 15:38
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
These Analysts Just Made A Significant Downgrade To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) EPS Forecasts
One thing we could say about the analysts on Heron Therapeutics, Inc. ( NASDAQ:HRTX ) - they aren't optimistic, having...
Simply Wall St. · 08/15 07:35
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HRTX. Analyze the recent business situations of Heron Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HRTX stock price target is 33.00 with a high estimate of 60.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 295
Institutional Holdings: 124.71M
% Owned: 122.37%
Shares Outstanding: 101.91M
TypeInstitutionsShares
Increased
63
11.87M
New
36
11.81M
Decreased
47
5.85M
Sold Out
37
5.06M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.68%
Pharmaceuticals & Medical Research
-0.57%
Key Executives
Chairman/Chief Executive Officer/Director
Barry Quart
President
John Poyhonen
Chief Operating Officer/Executive Vice President
David Szekeres
Executive Vice President/Director
Kimberly Manhard
Senior Vice President/Chief Scientific Officer
Thomas Ottoboni
Senior Vice President
Michael Mathews
Chief Accounting Officer/Vice President
Lisa Peraza
Vice President/Director of Human Resources
Sean Ristine
Vice President
John Arthur
Other
Christopher Storgard
Lead Director/Independent Director
Craig Johnson
Independent Director
Stephen Davis
Independent Director
Christian Waage
No Data
  • All
  • Financials
  • Insiders
More
About HRTX
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.